Cancer statistics, 2013
- PMID: 23335087
- DOI: 10.3322/caac.21166
Cancer statistics, 2013
Abstract
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. A total of 1,660,290 new cancer cases and 580,350 cancer deaths are projected to occur in the United States in 2013. During the most recent 5 years for which there are data (2005-2009), delay-adjusted cancer incidence rates declined slightly in men (by 0.6% per year) and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.5% per year in women. Overall, cancer death rates have declined 20% from their peak in 1991 (215.1 per 100,000 population) to 2009 (173.1 per 100,000 population). Death rates continue to decline for all 4 major cancer sites (lung, colorectum, breast, and prostate). Over the past 10 years of data (2000-2009), the largest annual declines in death rates were for chronic myeloid leukemia (8.4%), cancers of the stomach (3.1%) and colorectum (3.0%), and non-Hodgkin lymphoma (3.0%). The reduction in overall cancer death rates since 1990 in men and 1991 in women translates to the avoidance of approximately 1.18 million deaths from cancer, with 152,900 of these deaths averted in 2009 alone. Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket and other underserved populations.
Copyright © 2012 American Cancer Society, Inc.
Similar articles
-
Cancer statistics, 2012.CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4. CA Cancer J Clin. 2012. PMID: 22237781
-
Cancer statistics, 2015.CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5. CA Cancer J Clin. 2015. PMID: 25559415
-
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36. doi: 10.3322/caac.20121. Epub 2011 Jun 17. CA Cancer J Clin. 2011. PMID: 21685461
-
Cancer statistics, 2004.CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29. doi: 10.3322/canjclin.54.1.8. CA Cancer J Clin. 2004. PMID: 14974761 Review.
-
Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99. doi: 10.1093/jnci/djg040. J Natl Cancer Inst. 2003. PMID: 12953083 Review.
Cited by
-
Targeting DDX3 with a small molecule inhibitor for lung cancer therapy.EMBO Mol Med. 2015 May;7(5):648-69. doi: 10.15252/emmm.201404368. EMBO Mol Med. 2015. PMID: 25820276 Free PMC article.
-
BM-MSCs promote prostate cancer progression via the conversion of normal fibroblasts to cancer-associated fibroblasts.Int J Oncol. 2015 Aug;47(2):719-27. doi: 10.3892/ijo.2015.3060. Epub 2015 Jun 22. Int J Oncol. 2015. PMID: 26095189 Free PMC article.
-
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.Cancer Chemother Pharmacol. 2015 May;75(5):907-16. doi: 10.1007/s00280-015-2708-9. Epub 2015 Feb 28. Cancer Chemother Pharmacol. 2015. PMID: 25724156 Free PMC article. Clinical Trial.
-
miR-106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN.Int J Clin Exp Pathol. 2015 Apr 1;8(4):3827-34. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26097565 Free PMC article.
-
Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study.Front Immunol. 2022 Aug 26;13:944062. doi: 10.3389/fimmu.2022.944062. eCollection 2022. Front Immunol. 2022. PMID: 36091003 Free PMC article. Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous